Can the RSV vaccine protect vulnerable cancer survivors?
NCT ID NCT07296120
First seen Jan 08, 2026 · Last updated May 16, 2026 · Updated 20 times
Summary
This study looks at whether the RSV vaccine (Abrysvo) can help people with blood cancers who have had a bone marrow transplant or CAR-T cell therapy build immunity against RSV. About 30 adults will get the vaccine, and researchers will measure their antibody levels before and after vaccination. The goal is to see if the vaccine triggers a strong enough immune response to protect against serious RSV infection.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RSV IMMUNIZATION are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Cooper University Hospital
Camden, New Jersey, 08103, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.